Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
50.88
+0.76 (+1.52%)
Streaming Delayed Price
Updated: 3:46 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy
February 16, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
February 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
February 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Tomorrow's Innovators: Kwame Sarpong
December 06, 2021
SOURCE: Bristol Myers Squibb Company
Via
3BL Media
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
February 14, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
February 09, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
February 08, 2022
From
Bristol Myers Squibb
Via
Business Wire
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
February 04, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
February 04, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
January 28, 2022
From
Bristol Myers Squibb
Via
Business Wire
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
February 02, 2022
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials...
Via
FinancialNewsMedia
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
January 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
January 27, 2022
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,...
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference
January 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
January 04, 2022
From
Bristol Myers Squibb
Via
Business Wire
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
December 21, 2021
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...
Via
FinancialNewsMedia
Exposures
Product Safety
Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022
December 17, 2021
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
December 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
December 14, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
December 13, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results
December 11, 2021
From
Bristol Myers Squibb
Via
Business Wire
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
December 10, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY
December 03, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
December 03, 2021
From
Bristol Myers Squibb
Via
Business Wire
Encouraging Recruitment of Diverse Talent in the Biopharma Industry
December 02, 2021
SOURCE: Bristol Myers Squibb Company
Via
3BL Media
Topics
Supply Chain
Exposures
Supply Chain
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
November 29, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
November 23, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
November 19, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
November 18, 2021
From
Bristol Myers Squibb
Via
Business Wire
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
November 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.